Novavax 過去の業績

過去基準チェック /06

Novavaxの収益は年間平均-9.4%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間7.7% 26.7%割合で増加しています。

主要情報

-9.4%

収益成長率

3.0%

EPS成長率

Biotechs 業界の成長	14.2%
収益成長率	26.7%
株主資本利益率	n/a
ネット・マージン	-32.2%
前回の決算情報	30 Sep 2024

Recent updates

収支内訳

Novavax の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

BUL:NVV1 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
30 Sep 24	885	-285	405
30 Jun 24	988	-294	446
31 Mar 24	997	-399	427
31 Dec 23	984	-545	457
30 Sep 23	1,050	-549	464
30 Jun 23	1,597	-587	479
31 Mar 23	1,359	-1,155	505
31 Dec 22	1,982	-658	489
30 Sep 22	1,847	-1,322	411
30 Jun 22	1,291	-1,476	366
31 Mar 22	1,403	-1,318	331
31 Dec 21	1,146	-1,744	298
30 Sep 21	1,204	-1,075	273
30 Jun 21	1,182	-950	252
31 Mar 21	919	-615	196
31 Dec 20	476	-418	143
30 Sep 20	205	-273	92
30 Jun 20	50	-93	43
31 Mar 20	18	-115	35
31 Dec 19	19	-133	34
30 Sep 19	16	-150	35
30 Jun 19	21	-177	36
31 Mar 19	29	-182	34
31 Dec 18	34	-185	34
30 Sep 18	39	-186	34
30 Jun 18	39	-186	34
31 Mar 18	35	-186	34
31 Dec 17	31	-184	34
30 Sep 17	26	-190	34
30 Jun 17	21	-212	40
31 Mar 17	17	-247	45
31 Dec 16	15	-280	47
30 Sep 16	16	-302	47
30 Jun 16	19	-269	43
31 Mar 16	31	-210	36
31 Dec 15	36	-157	31
30 Sep 15	37	-110	27
30 Jun 15	39	-96	23
31 Mar 15	33	-94	21
31 Dec 14	31	-83	20
30 Sep 14	33	-65	18
30 Jun 14	29	-61	17
31 Mar 14	25	-56	15
31 Dec 13	21	-52	15

質の高い収益: NVV1は現在利益が出ていません。

利益率の向上: NVV1は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NVV1は利益が出ておらず、過去 5 年間で損失は年間9.4%の割合で増加しています。

成長の加速: NVV1の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: NVV1は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: NVV1の負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Novavax 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings released: US$0.76 loss per share (vs US$1.26 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$1.09 (vs US$0.65 in 2Q 2023)

Novavax, Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$1.06 loss per share (vs US$3.41 loss in 1Q 2023)

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Recent updates

Third quarter 2024 earnings released: US$0.76 loss per share (vs US$1.26 loss in 3Q 2023)

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Novavax, Inc Announces Update on Covid-19-Influenza Combination and Stand-Alone Influenza Phase 3 Trial

Forecast breakeven date pushed back to 2026

Novavax, Inc. Updated 2024-2025 Nuvaxovid™ Covid-19 Vaccine Receives Authorization in the EU

Forecast breakeven date moved forward to 2025

Novavax Announces Availability of Updated Covid-19 Vaccine with Emergency Use Authorization from FDA

Novavax Announces That Novavax COVID-19 Vaccine, Adjuvanted Receives Emergency Use Authorization from the U.S. Food and Drug Administration

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.09 (vs US$0.65 in 2Q 2023)

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

Novavax, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

President of Research & Development recently sold €355k worth of stock

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$1.06 loss per share (vs US$3.41 loss in 1Q 2023)

No longer forecast to breakeven

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax, Inc., Annual General Meeting, Jun 13, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast breakeven date moved forward to 2025

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Forecast to breakeven in 2026

Forecast breakeven date pushed back to 2026

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

New minor risk - Profitability

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

No longer forecast to breakeven

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

No longer forecast to breakeven

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Third quarter 2022 earnings released: US$2.15 loss per share (vs US$4.31 loss in 3Q 2021)

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Novavax, Inc. Announces Positive Results from Phase 1/2 Clinical Trial of Its COVID-19-Influenza Combination (CIC) Vaccine Candidate

過去基準チェック /06